STAGNI, FIORENZA
 Distribuzione geografica
Continente #
NA - Nord America 1528
EU - Europa 785
AS - Asia 218
AF - Africa 83
SA - Sud America 2
Continente sconosciuto - Info sul continente non disponibili 1
OC - Oceania 1
Totale 2618
Nazione #
US - Stati Uniti d'America 1520
GB - Regno Unito 248
IT - Italia 214
DE - Germania 123
CN - Cina 112
SE - Svezia 78
TG - Togo 58
IN - India 50
VN - Vietnam 48
FR - Francia 26
RU - Federazione Russa 25
BE - Belgio 20
ZA - Sudafrica 19
UA - Ucraina 17
EE - Estonia 16
CA - Canada 8
NG - Nigeria 5
GR - Grecia 4
NL - Olanda 4
PL - Polonia 4
IR - Iran 3
RO - Romania 3
BR - Brasile 2
JP - Giappone 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AU - Australia 1
BD - Bangladesh 1
CH - Svizzera 1
FI - Finlandia 1
HR - Croazia 1
SA - Arabia Saudita 1
SC - Seychelles 1
TR - Turchia 1
Totale 2618
Città #
Chandler 247
Fairfield 237
Southend 231
Houston 126
Wilmington 114
Seattle 110
Ann Arbor 101
Bologna 101
Ashburn 98
Woodbridge 96
Cambridge 68
Princeton 60
Lomé 58
Dong Ket 47
Redmond 33
Frankfurt am Main 30
Falls Church 29
Westminster 21
Beijing 19
Brussels 19
Nanjing 17
Padova 16
San Diego 15
Shenyang 15
Berlin 14
Jinan 10
Redwood City 10
Saint Petersburg 10
Hebei 9
Turin 8
Changsha 7
Boardman 6
Des Moines 6
Toronto 6
Abeokuta 5
Nanchang 5
Tianjin 5
Bolzano 4
Norwalk 4
Piemonte 4
Rome 4
Venezia 4
Andover 3
Dearborn 3
Haikou 3
Monmouth Junction 3
Ravenna 3
Ardabil 2
Bremen 2
Calderara Di Reno 2
Christiansburg 2
Ferrara 2
Fuzhou 2
Guangzhou 2
Kyoto 2
Leawood 2
Los Angeles 2
Orange 2
Paris 2
Reggio Nell'emilia 2
Rimini 2
Shanghai 2
Taiyuan 2
Taizhou 2
Zhengzhou 2
Afragola 1
Anchorage 1
Aprilia 1
Barsinghausen 1
Bethesda 1
Boydton 1
Brindisi 1
Buffalo 1
Castenaso 1
Cesena 1
Chengdu 1
Costa Mesa 1
Edmonton 1
Fermo 1
Fremont 1
Gainesville 1
Garden City 1
Gemünden 1
Genova 1
Groningen 1
Hangzhou 1
Hanoi 1
Helsinki 1
Henderson 1
Izmir 1
Jiaxing 1
Kuban 1
Kuhardt 1
Lanzhou 1
Las Vegas 1
Leipzig 1
Mahé 1
Medford 1
Milan 1
Montreal 1
Totale 2115
Nome #
Age-related impairment of olfactory bulb neurogenesis in the Ts65Dn mouse model of Down syndrome 135
A flavonoid agonist of the TrkB receptor for BDNF improves hippocampal neurogenesis and hippocampus-dependent memory in the Ts65Dn mouse model of DS 132
null 130
Early Pharmacotherapy with Fluoxetine Rescues Dendritic Pathology in the Ts65Dn Mouse Model of Down Syndrome 122
Timing of Treatment with the Flavonoid 7,8-DHF Critically Impacts on Its Effects on Learning and Memory in the Ts65Dn Mouse 117
Long-term effect of neonatal inhibition of APP gamma-secretase on hippocampal development in the Ts65Dn mouse model of Down syndrome 115
Abnormal development of the inferior temporal region in fetuses with Down Syndrome 115
Lithium Restores Age Related Olfactory Impairment in the Ts65Dn Mouse Model of Down Syndrome 110
Epigallocatechin gallate: A useful therapy for cognitive disability in Down syndrome? 103
Inhibition of APP gamma-secretase restores Sonic Hedgehog signaling and neurogenesis in the Ts65Dn mouse model of Down syndrome 101
null 97
Subicular hypotrophy in fetuses with Down syndrome and in the Ts65Dn model of Down syndrome. 97
Neonatal therapy with clenbuterol and salmeterol restores spinogenesis and dendritic complexity in the dentate gyrus of the Ts65Dn model of Down syndrome 97
Neuroanatomical alterations and synaptic plasticity impairment in the perirhinal cortex of the Ts65Dn mouse model of Down syndrome 94
Pharmacotherapy with Fluoxetine Restores Functional Connectivity from the Dentate Gyrus to Field CA3 in the Ts65Dn Mouse Model of Down Syndrome 93
SNX27, a protein involved in down syndrome, regulates GPR17 trafficking and oligodendrocyte differentiation 92
Timing of therapies for downsyndrome: The sooner, the better 92
Neonatal treatment with cyclosporine A restores neurogenesis and spinogenesis in the Ts65Dn model of Down syndrome 91
Impaired brain mitochondrial bioenergetics in the ts65dn mouse model of down syndrome is restored by neonatal treatment with the polyphenol 7,8-dihydroxyflavone 90
null 83
Prenatal pharmacotherapy rescues brain development in a Down's syndrome mouse model. 76
Targeting APP/AICD in Down syndrome 73
Treatment with the flavonoid 7,8-Dihydroxyflavone: a promising strategy for a constellation of body and brain disorders 71
Treatment with corn oil improves neurogenesis and cognitive performance in the Ts65Dn mouse model of Down syndrome. 70
Neuroanatomical Alterations in Higher-Order Thalamic Nuclei of Fetuses With Down Syndrome 67
Early appearance of developmental alterations in the dendritic tree of the hippocampal granule cells in the Ts65Dn model of Down syndrome 58
Obstructive sleep apneas naturally occur in mice during REM sleep and are highly prevalent in a mouse model of Down syndrome 51
The flavonoid 7,8-DHF fosters prenatal brain proliferation potency in a mouse model of Down syndrome 45
Early appearance of dendritic alterations in neocortical pyramidal neurons of the Ts65Dn model of Down syndrome 36
Short- and long-term effects of neonatal pharmacotherapy with epigallocatechin-3-gallate on hippocampal development in the Ts65Dn mouse model of Down syndrome 20
Long-term effects of neonatal treatment with fluoxetine on cognitive performance in Ts65Dn mice. 17
Neurogenesis impairment: An early developmental defect in Down syndrome 14
Epigallocatechin-3-gallate: Linking the neurogenesis, hippocampus, and Down syndrome 7
The Challenging Pathway of Treatment for Neurogenesis Impairment in Down Syndrome: Achievements and Perspectives 4
Totale 2715
Categoria #
all - tutte 4067
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 4067


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2017/201843 0000 00 06 10360
2018/2019131 21702 516 77 9181929
2019/2020799 8524949 8979 94108 121674529
2020/2021499 68211073 1330 1247 56492595
2021/2022584 33272515 6842 5535 2637110111
2022/2023590 7416152121 6277 430 0000
Totale 2715